Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:55:55.962Z.
Calculation as of: 2026-10-06T19:55:55.962Z.
Quote observation: 2026-10-06T19:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
BlossomHill Therapeutics, Inc.
Market Cap
$505.14M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$504.84M
Price/FCF Ratio
1047.39
TTM Avg
838.04
3Y Avg
838.04
5Y Avg
838.04
Market Cap
$502.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$499.40M
Price/FCF Ratio
18.69
TTM Avg
15.64
3Y Avg
12.14
5Y Avg
236.08
Market Cap
$516.76M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $505.14M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $504.84M | 1047.39 | 838.04 | 838.04 | 838.04 |
| Crescent Biopharma, Inc. (CBIO)vs › | $502.74M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $502.20M | N/A | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $499.40M | 18.69 | 15.64 | 12.14 | 236.08 |
| Oculis Holding AG (OCS)vs › | $494.52M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $518.27M | N/A | 0.26 | 0.26 | 0.26 |
| Immix Biopharma, Inc. (IMMX)vs › | $522.51M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $486.67M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
